Metabolic acidosis is a common complication of chronic kidney disease (CKD) that is associated with CKD progression, all-cause mortality, and adverse effects on bone and muscle¹. Metabolic acidosis poses a significant health risk to around 3 million patients with CKD in the United States. Advances in the care of patients with CKD and metabolic acidosis have been hampered by the lack of data on the natural history of the condition.
While there are far more patients with non-dialysis-dependent CKD than with end-stage kidney disease, most registries in nephrology are for patients who have initiated dialysis or undergone a kidney transplant².
ULTIMA-CKD is the first registry for patients with metabolic acidosis and non-dialysis CKD; it is an ongoing, prospective, longitudinal, observational study.
The objectives of ULTIMA-CKD are to understand the natural course of metabolic acidosis by describing clinical characteristics and management of this population over time; to identify characteristics associated with better/worse health outcomes; and to assist nephrologists in identifying trends within their practices.
We are currently enrolling sites in the US to participate in the ULTIMA-CKD registry.
If you have any questions, please call us at 888-TRICIDA (888-874-2432) or e-mail: ultima-ckd@tricida.com
¹Kraut JA, Madias NE. Adverse effects of the metabolic acidosis of chronic kidney disease. Adv Chronic Kidney Dis 2017; 24: 289–97.
²Centers for Disease Control and Prevention. Chronic Kidney Disease Initiative. http://cdc.gov/kidneydisease/basics.html. Accessed February 27, 2020